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Abstract
Background: Urinary biomarkers for bladder cancer detection are constrained by inadequate sensitivity or specificity. Here
we evaluate the diagnostic accuracy of Mcm5, a novel cell cycle biomarker of aberrant growth, alone and in combination
with NMP22.
Methods: 1677 consecutive patients under investigation for urinary tract malignancy were recruited to a prospective
blinded observational study. All patients underwent ultrasound, intravenous urography, cystoscopy, urine culture and
cytologic analysis. An immunofluorometric assay was used to measure Mcm5 levels in urine cell sediments. NMP22 urinary
levels were determined with the FDA-approved NMP22H Test Kit.
Results: Genito-urinary tract cancers were identified in 210/1564 (13%) patients with an Mcm5 result and in 195/1396 (14%)
patients with an NMP22 result. At the assay cut-point where sensitivity and specificity were equal, the Mcm5 test detected
primary and recurrent bladder cancers with 69% sensitivity (95% confidence interval = 62–75%) and 93% negative predictive
value (95% CI = 92–95%). The area under the receiver operating characteristic curve for Mcm5 was 0.75 (95% CI = 0.71–0.79)
and 0.72 (95% CI = 0.67–0.77) for NMP22. Importantly, Mcm5 combined with NMP22 identified 95% (79/83; 95% CI = 88–
99%) of potentially life threatening diagnoses (i.e. grade 3 or carcinoma in situ or stage $pT1) with high specificity (72%,
95% CI = 69–74%).
Conclusions: The Mcm5 immunoassay is a non-invasive test for identifying patients with urothelial cancers with similar
accuracy to the FDA-approved NMP22 ELISA Test Kit. The combination of Mcm5 plus NMP22 improves the detection of UCC
and identifies 95% of clinically significant disease. Trials of a commercially developed Mcm5 assay suitable for an end-user
laboratory alongside NMP22 are required to assess their potential clinical utility in improving diagnostic and surveillance
care pathways.
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Introduction
Urothelial cell carcinoma (UCC) of the urinary bladder is the
4th most common cancer in the US, with an estimated 73510 new
cases and 14880 deaths from bladder cancer in 2012 [1].
Cystoscopy is the standard method of bladder tumour detection,
however it is an invasive, uncomfortable and costly procedure
which results in urinary infection in up to 5% of cases [2].
Detection of bladder cancer with a non-invasive tumour marker
test could potentially improve the management of the disease by
increasing the accuracy and decreasing the morbidity associated
with current diagnostic and surveillance pathways. Through
reduced frequency of cystoscopies, improvements in patient’s
quality of life and cost efficiency could be seen.
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e40305
Urinary biomarkers for the detection of bladder cancer hold
great promise and while numerous markers have regulatory
approval none have been accepted as a standard diagnostic
procedure [3]. Urinary cytology remains the most widely utilized
because of high specificity although poor sensitivity. Novel
technologies and biomarkers, however, have the potential to
improve diagnostic accuracy, with the most effective diagnostic
and surveillance strategies to date utilizing photodynamic cystos-
copy and biomarkers [4]. Nuclear matrix protein 22 (NMP22), for
example, is a nuclear mitotic apparatus protein that regulates
chromatid and daughter cell separation [5,6] and has emerged as
one of the promising urinary biomarkers for UCC [3]. The FDA-
approved, laboratory-based quantitative NMP22H Test Kit
immunoassay (Matritech, Freiburg, Germany) and a qualitative
point-of-care test, NMP22H BladderChekH (Matritech; H symbol
omitted hereafter), are now available for clinical use. However,
although urinary NMP22 levels are elevated in bladder cancer,
dead and dying urothelial cells in many non-malignant and
inflammatory conditions can also release NMP22, thus reducing
specificity. Moreover, a wide marked range in test performance
has been reported among different studies using NMP22, with
sensitivity ranging from 33% to 100% and specificity from 40% to
93% [4].
The constrained accuracy of available biomarkers, along with
their expense, has therefore limited introduction of urinary
biomarkers into routine clinical practice. Hence there remains
an urgent need to identify new biomarkers that might improve
diagnostic accuracy, either when used in isolation or in
combination with existing biomarker tests [7].
The DNA replication initiation machinery represents a final
and critical step in growth control downstream of complex
redundant oncogenic signalling pathways and is therefore a
potentially attractive diagnostic and therapeutic target [8].
Proteins of the minichromosome maintenance (Mcm) family
(Mcm2-7, collectively referred to as MCM), assemble into
hexameric complexes that have DNA helicase activity, which is
essential for initiation of DNA synthesis [9,10]. In epithelial-lined
organ systems MCM proteins become dysregulated and overex-
pressed in hyperproliferative dysplastic (preinvasive) and malig-
nant states, [8,11–13]. Indeed the degree of expression of Mcm2
and Mcm5 has been shown to predict recurrence and death in
patients with bladder cancer [14–16]. Mcm2-7 protein expression
in normal epithelium is restricted to the basal stem/transit
compartments and is absent from surface layers as cells adopt a
fully differentiated phenotype. In premalignant/dysplastic epithe-
lial lesions there is an expansion of the proliferative compartment
coupled to arrested differentiation, resulting in the appearance of
cycling MCM-positive cells in superficial layers. The detection of
exfoliated MCM-positive cells in clinical samples therefore
provides a potentially sensitive method for detecting preinvasive
and invasive cancers [8,17,18]. In a proof-of-principle study we
previously showed that elevated Mcm5 levels in cells in urine
sediments is predictive of the presence of bladder cancer [19].
The aim of this study was to evaluate Mcm5 as a biomarker for
detection of bladder cancer alone, in comparison and in
combination with NMP22. The prospective blinded observational
trial utilized an immunofluorometric assay to measure Mcm5 and
the FDA-approved NMP22 Test Kit.
Methods
Study Subjects
Single voided urine specimens were obtained from 1677
patients attending a one stop diagnostic clinic for investigation of
haematuria. The diagnosis was established following assessment by
cystoscopy, upper urinary tract imaging, urine cytology and
culture. Histological confirmation of bladder cancer at subsequent
trans-urethral resection was the reference standard and all patients
were followed for a period of six months from the time of initial
investigations. Patients with a history of recent genito-urinary
instrumentation or surgery within the previous two weeks were
excluded. Patients with a history of concomitant malignancy or
other malignancy within five years prior to study were also
excluded. With these exceptions all consecutive patients attending
for investigation during the study period were approached for
recruitment into the trial.
Urine samples were split equally for: (i) urinalysis and
microbiological culture, (ii) cytological analysis, (iii) Mcm5
measurement and (iv) NMP22 measurement. Patients underwent
upper urinary tract imaging including ultrasound and intravenous
urography. Male patients were examined by digital rectal
examination for the presence of clinically detectable prostatic
disease. Prostate-specific antigen (PSA) testing was not mandated
and PSA levels were checked in a proportion of cases in whom
cancer was suspected or who requested the test. If PSA levels were
elevated patients were offered trans-rectal ultrasound guided core
biopsies of the prostate. Typically all haematuria tests were
completed within 24 hours and within two weeks for all patients.
Clinical data were entered into a database prospectively prior to
Mcm5 and NMP22 analysis. The reference standard for detection
of bladder cancer was pathological confirmation following trans-
urethral resection.
Urine samples were analyzed in a blinded fashion for Mcm5
detection, NMP22 testing, and cytologic analyses. On completion
of the study, we decoded the patient data and compared
immunofluorometric Mcm5 signals and NMP22 results with
clinical diagnoses based on cystoscopy, biopsy histology, imaging
and urine cytology. Staging and grading of malignant tumours was
performed by a specialist uro-pathologist using the TNM (tumour-
node-metastasis) classification system [20] and the 1973 World
Health Organization (WHO) grading system respectively [21].
Ethics Statement
Ethical approval was obtained from the Joint UCL/UCLH
Committees on the Ethics of Human Research (04/Q0502/1),
Addenbrooke’s Hospital Ethics Committee (00/236) and the
Newcastle and North Tyneside Research Ethics Committee
(2002/161). Written informed consent was received from all
participants.
Urine Cytology
Urine samples (50 mL) were centrifuged at 1500 g for 5 min.
Cytospin preparations were prepared on poly-L-lysine coated
slides using Shandon cytospin tubes and a cytocentrifuge
according to the manufacturer’s instructions (Thermo Shandon,
Runcorn, UK). Samples were fixed in industrial methylated spirits
and stained using the Papanicolaou technique for smears [20].
Specimens were evaluated by a consultant cytologist experienced
in uro-pathology. Cytology was scored as positive if atypical or
malignant cells were identified.
NMP22 Assay
NMP22 was measured by enzyme-linked immunosorbent assay
(ELISA) using the FDA-approved NMP22 Test Kit produced by
Matritech (Freiburg, Germany). The assay run on a Dade Behring
BEP 2000 automated ELISA processor (now Siemens Healthcare).
All reagents, calibrators and controls were prepared as recom-
mended by the manufacturer. All standards, quality controls and
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samples were analyzed in duplicate. Results were calculated using
the data processing software supplied with the BEP 2000. The
lower limit of detection of the assay was found to be 2 U/mL.
Samples with concentrations greater than the top standard were
repeated after dilution in assay buffer. The between-batch
coefficient of variation was 13.3% at a concentration of 11.3 U/
mL, 8.8% at 34 U/mL and 9.5% at 65 U/mL. A result for the
NMP22 test was available in 1396 patients, including 195 patients
(14%) with a urothelial tumour.
Immunofluorometric Assay to Measure Mcm5 Levels in
Urine Sediments
Mcm5 was measured by two-site time-resolved fluorescence
immunoassay on the AutoDELFIA analyzer (Perkin Elmer). All
standards, quality controls and urine samples were prepared and
processed as described [19]. Nunc Maxisorp microtiter plates
(Perkin Elmer) were coated with 12A7 mouse anti-human
Mcm5 monoclonal antibody [19] at a concentration of 8 mg/L
by Dako UK Ltd (Ely, UK). A large batch (approximately 200)
of plates were prepared by Dako and used throughout the
study. Plates were received pre-blocked and ready for use. A
second mouse anti-human Mcm5 monoclonal antibody (4B4)
[19] was conjugated with europium by Dako. The europium-
labelled antibody was at a concentration of 1.75 mg/mL. HeLa
S3 cells were purchased commercially (Health Protection
Agency Culture Collections, Porton Down, UK) and the assay
was calibrated with processed HeLa cell standards at a
concentration of 150000 cells/well. A series of standards
spanning the concentration range 150000 to 1500 cells/well
were prepared by diluting the stock standard in phosphate
buffered saline containing 0.04% SDS and 0.02% sodium azide.
Quality control samples containing four different concentrations
of HeLa cells were analyzed at the beginning and end of each
batch. The protocol for the AutoDELFIA assay was as follows.
50 mL standard, sample or quality control was added (in
duplicate) to the antibody-coated microtiter plate along with
100 mL DELFIA multibuffer (Perkin Elmer product code 1380–
3614). The plate was incubated for 2.5 h with continuous
shaking. The plate was then washed four times with DELFIA
wash buffer (Perkin Elmer product code B117-100). Europium-
labelled detection antibody 4B4 was diluted 1:1,800 in DELFIA
multibuffer. 100 mL of diluted antibody was added to each well
and the plate incubated for a further 4 h with continuous
shaking. The plate was then washed six times with DELFIA
wash buffer and 200 mL DELFIA enhancement solution (Perkin
Elmer product code B118-100) was added to each well. The
plate was incubated on a shaker for a further 10 min. The
amount of europium in each well was measured on the
AutoDELFIA plate reader. Data were automatically transferred
to a MultiCalc software package (Perkin Elmer), which was used
to generate a calibration curve and calculate the concentration
of the unknowns. The lower limit of detection of the assay was
found to be 1000 cells/well. Samples with concentrations
greater than the top standard were repeated after dilution in
the standard dilution buffer. The between-batch coefficient of
variation was 11.5% at a concentration of 2648 cells/well and
11.0% at 26382 cells/well. A result for the immunofluorometric
Mcm5 test was available in 1564 patients including 210 patients
(13%) with a urothelial tumour.
Statistical Analysis
Sensitivity and specificity characteristics of Mcm5 and NMP22
for the detection of UCC of the bladder are presented as receiver
operating characteristic (ROC) curves. The area under the
nonparametric ROC curve was used to assess the overall
diagnostic performance of each test. Three cut-points were used
to demonstrate test performance under different circumstances for
Mcm5 as follows: (i) the lower detection limit of the assay where
sensitivity of the test was maximal (1000 cells/well) (ii) sensitivity
equal to specificity (2150 cells/well) and (iii) 95% specificity (8500
cells/well). Negative predictive value (NPV) and positive predictive
value (PPV) were also estimated. An exact 95% confidence interval
(CI) for each proportion, including sensitivity, specificity and
predictive values for Mcm5 and NMP22, was derived assuming a
binomial distribution. The manufacturer’s recommended cut-
point for NMP22, 10 U/ml was utilized for all analyses unless
otherwise specified.
False positive rates (FPR) for the Mcm5 and NMP22 tests in
patients with benign diagnosis were compared with clear normal
patients using a Chi-squared test. The Mcm5 and NMP22 values
were summarized using medians and interquartile ranges (IQR)
and compared with the clear normal patients using the Mann-
Whitney U-test. For each biomarker, the ROC analysis was
repeated for males and females separately and the areas under the
ROC curves were compared using a Chi-squared test with one
degree of freedom. ROC analysis was also undertaken to examine
the sensitivity of the main results to the exclusion of those with
benign disease. The values of the urinary biomarkers for patients
with different tumour grades and stages and normal patients were
compared using Mann-Whitney U-tests between neighbouring
categories, and using the Jonckheere-Terpstra test for trend across
grades and stages. The Chi-squared test for linear by linear
association was used to assess the evidence for a trend in the false
positive rates by increasing tumour grade and stage. The sensitivity
determined for urinary cytology was compared with that of the
immunofluorometric Mcm5 test using McNemar’s test for paired
proportions. The accuracy of a biomarker was defined as the value
of sensitivity and specificity where the cut-point provided these to
be equal. The accuracy of the two biomarker tests was compared
using McNemar’s test. McNemar’s test was also used to compare
the sensitivity of cytology with that of each biomarker at cut-points
providing the same specificity as observed for cytology. Spearman
correlation was used to assess the degree to which the biomarkers
were distinctive in UCC case and in normal control groups. All
statistical tests were two-tailed, and a 5% level was used to indicate
statistical significance.
A multi-ROC analysis [22] was performed to determine the
additional performance resulting from using both biomarkers
together. In this analysis, NMP22 was kept fixed at the
recommended cut-point of 10 U/mL and Mcm5 was included
with a varying cut-point. Raised values of either marker could
predict positive for UCC. The additional performance of Mcm5
over that obtained from NMP22 (10 U/mL cut-point) was
assessed using the nonparametric area under the multi-ROC
curve, and assessed for statistical significance using a Chi-squared
test with one degree of freedom. In order to demonstrate test
performance, Mcm5 was then fixed at the cut-point that provided
equal sensitivity and specificity on the multi-ROC curve from
using the combined markers. This combination test accuracy was
compared with the test accuracy provided by use of NMP22 alone
using McNemar’s test.
Results
Demographics and Clinical Investigation
The demographic characteristics, mode of presentation, final
diagnosis, and tumour grade and stage for the 1677 patients
included in this study are summarized in Table 1. The study
Mcm5 and NMP22 in the Diagnosis of Bladder Cancer
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population was predominantly male (62%) and had a mean age of
60.7 years (standard deviation, 16.3 years). Of those with a
recorded presentation, 54% had visible haematuria and 46% had
non-visible haematuria. These patients were newly presenting
cases, although four patients recruited, later revealed a previous
history of UCC. Investigations were omitted in a proportion of
cases as follows: cystoscopy was not performed in 20 patients,
ultrasound scan in 186 patients and intravenous urography in 223
patients. Urine cytology was unavailable for 109 patients due to
insufficient sample collection or, alternatively, because the test was
not undertaken. Neither ultrasound scan nor intravenous urogra-
phy was performed in 77 patients. All patients had a clinical
diagnosis attributed to them by their clinician. Data were not
formally collected on the adverse effects of standard clinical testing
and no adverse effects of urinary testing for Mcm5 or NMP22
were recorded.
Following clinical investigation, urinary tract tumours were
identified in 222/1677 patients (13%). Nearly all tumours were
UCCs, but, investigation also identified one case of adenocarci-
noma and two cases of squamous cell carcinoma of the bladder.
The UCCs were predominantly bladder tumours, with only seven
patients with upper tract tumours. The upper tract UCCs are
included alongside the bladder tumours for the analysis reported
below. The diagnoses in the remaining patients included other
malignancies, benign lesions or cysts of the kidney, benign
inflammatory and congenital conditions, urolithiasis, benign
prostatic hyperplasia and nephrological diseases. The diagnoses
are listed in Table S1. As a component of the diagnostic pathway,
urinary cytology had a sensitivity of 9% (95% CI, 5–14%;
including atypical cytology as positive), specificity of 88% (95% CI,
86–89%) and PPV of 10% (95% CI, 7–15%).
Mcm5 and NMP22 Test Performance
The Mcm5 test discriminated, with high specificity and
sensitivity, between patients with and without bladder cancer, as
demonstrated by the large area under the ROC curve (AUC) (0.75
[95% CI= 0.71–0.79]) (Figure 1), statistically significantly larger
than the area assumed by the null hypothesis (0.5; P,0.001) and
based on 210 and 1354 patients respectively with and without
UCC.
The sensitivity, specificity, and positive and negative predictive
values (PPV and NPV) for Mcm5 are shown in Table 2. The cut-
point analysis (cut-points correspond to (i) lower detection limit of
the assay; (ii) where sensitivity is equal to specificity, and (iii)
specificity of 95% for all patients tested), demonstrated a wide
range of test performance levels (Table 2). At the lower detection
limit of the assay, the test had 80% (167/210) (95% CI= 73–85%)
sensitivity and 20% (167/846) (95% CI= 17–23%) PPV. When
sensitivity is equal to specificity, the test had 69% (145/210) (95%
CI= 62–75%) sensitivity and 26% (145/565) (95% CI= 22–30%)
PPV. At 95% specificity (1286/1354), the test had 42% (89/210)
(95% CI= 36–49%) sensitivity and 57% (89/157) (95% CI=49–
65%) PPV.
The NMP22 test discriminated with high specificity and
sensitivity as demonstrated by the large AUC (0.72 [95%
CI= 0.67–0.77]; null hypothesis [0.5; P,0.001] (Figure 1)) and
based on 195 and 1201 patients respectively with and without
UCC. The sensitivity, specificity, and positive and negative
predictive values for NMP22 at the recommended 10 U/ml cut-
point are shown in Table 2. Sensitivity was 53% (104/195) (95%
CI= 46–60%) and PPV 36% (104/291) (95% CI= 30–42%).
In order to assess the performance of the test in patients with
different stages and grades of disease the True Positive Rate (TPR)
was calculated for Mcm5 (at the different cut-points), NMP22 and
Table 1. Patient demographics and clinicopathological data.
n % mean SD median IQR
Patients recruited 1677
Age, years 60.7 16.3 63 49–73
Gender Male 1040 62
Female 637 38
Bladder/upper tract tumor Positive 222 13
Negative 1455 87
Grade a 1 26 12
2 129 58
3 (including CIS) 66 30
Stage T0 1455
Tx 1
Tis 8 4b
Ta 122 55
T1 50 23
$T2 41 18
Initial referral Non-visible haematuria 711 46c
Visible haematuria 851 54
Unrecorded 115
Abbreviations: CIS, carcinoma in situ; IQR, interquartile range; SD, standard deviation.
an = 221.
bPercentage of patients excluding those with stage T0 and Tx.
cPercentage of recorded cases only.
doi:10.1371/journal.pone.0040305.t001
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cytology for muscle invasive vs non-muscle invasive (Table S2) and
across grades (Table S3). Test performance improved for all tests
in higher stage and grade categories.
Where the specificity of NMP22 (cut-point 12.1) was the same
as that of positive cytology (88%; 989/1128), the sensitivity of
NMP22 was significantly higher (P,0.001) (51%; 91/177 versus
8%; 14/177). Where the specificity of Mcm5 (5150-cell cut-point)
was the same as that of cytology (87%; 1109/1271) the sensitivity
of Mcm5 was significantly higher (P,0.001) (52%; 100/193 versus
9%; 17/193).
Biomarker False Positive Analysis
False positives were found in 400/1301 (31%) of clear normal
and benign diagnosis patients with the Mcm5 test at the 2150-cell
cut-point. There was a significantly higher rate of false positive
results in female patients, 38% (200/520) compared to males 26%
(200/781) (P,0.001). Urinary Mcm5 levels were also significantly
higher in normal/benign females compared to males (median
1560 cells/well [IQR=,1000–3675 cells/well] vs median ,1000
cells/well [IQR=,1000–2180 cells/well], P,0.001). Further-
more, compared to normal patients, those with, urinary calculi
had a significantly higher false positive rate (44% [47/106] vs 30%
[201/661], P = 0.004) and higher urinary levels of Mcm5 protein
(median 1840 cells/well [,1000–3963 cells/well] vs 1040 cells/
well [,1000–2645 cells/well], P,0.001; Table 3). There was no
evidence of an association between the false positive rate and any
of the other benign groups including inflammatory conditions and
benign prostatic hyperplasia. In the clear normal and benign
patient groups there were no significant differences (P = 0.99) in
NMP22 levels between males and females. A raised NMP22 signal
and increased false positive rate was observed for those patients
with urinary tract infections (FPR: 22% vs 11%, P=0.001;
median NMP22 result: 3.35 U/mL vs 2.2 U/mL, P,0.001) and
urinary calculi (FPR: 23% vs 11%, P= 0.001; NMP22:2.55 U/mL
vs 2.2 U/mL, P= 0.047) (Table 3).
The ROC analysis for Mcm5 and NMP22 was repeated
observing the results in all males and females (Table S4 and Figure
S1). There were no significant differences in AUC values for
Mcm5 between males and females (P = 0.76), but there was a
significant difference in the NMP22 AUC value between males
and females (AUC 0.69 for males vs 0.80 for females, P = 0.025),
apparently related to the greater NMP22 sensitivity in females.
Biomarker False Negative Analysis
Table 4 and Table S5 show the false negative rates of urinary
Mcm5 and NMP22 grouped by tumour grade and stage. There
was evidence of a decreasing trend in the false-negative rate with
increasing tumour grade and stage for both urinary biomarkers.
For grades 1, 2 and 3 respectively, the false negative rates for
urinary Mcm5 at the 2150-cell cut-point were 52% (95% CI= 31–
73%), 37% (95% CI=28–46%) and 11% (95% CI=4–22%;
trend P,0.001). For NMP22 at the 10 U/mL cut-point, the
corresponding false negative rates were 80% (95% CI= 59–93%),
49% (95% CI=40–59%) and 25% (95% CI= 14–40%; trend
P,0.001). Similar trends were observed for tumour stage. A
significant decrease in the amplitude of the Mcm5 and NMP22
signal with lower tumour grade and stage was observed, in keeping
with the increasing false negative rates observed for these groups
(Table 4 and Table S5).
Combined Biomarker Multi-ROC Analysis
There were 183 bladder UCCs and 1100 normal patients with
assay data available for both urinary markers. For these patients,
an Mcm5 cut-point of 2180 cells/well provided equal sensitivity
and specificity of 71% (130/183 and 777/1100), and for NMP22 a
cut-point of 4.6 U/mL provided equal sensitivity and specificity of
67% (123/183 and 742/1100). Although there was modestly
greater performance of Mcm5 compared with NMP22 in terms of
accuracy (71% versus 67%, difference of 3.3%, 95% CI=20.2–
6.7%), this difference was not statistically significant (McNemar’s
test: P = 0.067).
The Spearman correlation coefficients between Mcm5 and
NMP22 were moderately high (rho= 0.54) for UCC cases and
negligible (rho= 0.08) for the normal group, indicating potential
for the biomarkers to provide distinct roles within a combination.
On the basis of multi-ROC analysis, the immunofluorometric
Mcm5 test, in combination with NMP22 at the recommended
10 U/mL cut-point, offers a statistically significant increase in
performance (P,0.001) compared with NMP22 alone at the
recommended cut-point (area under multi-ROC curve = 0.65,
95% CI= 0.58–0.71). As a demonstration, if either NMP22
exceeds 10 U/mL or Mcm5 exceeds the 4200-cell cut-point, this
combination provides sensitivity (131/183) and specificity (789/
Figure 1. Receiver operating characteristics curves for Mcm5
and NMP22 tests for the detection of bladder cancer in all
studied patients with valid test results.
doi:10.1371/journal.pone.0040305.g001
Table 2. Performance of Mcm5 and NMP22 tests for bladder
carcinoma detection for all patients with test results available.
Test Cut-point n
Sens,
% (CI)
Spec,
% (CI)
PPV,
% (CI)
NPV,
% (CI)
Mcm5 1000-cell 1564 80 (73–85) 50 (47–52) 20 (17–23) 94 (92–96)
2150-cell 1564 69 (62–75) 69 (66–71) 26 (22–30) 93 (92–95)
8500-cell 1564 42 (36–49) 95 (94–96) 57 (49–65) 91 (90–93)
NMP22 10 U/ml 1396 53 (46–60) 84 (82–86) 36 (30–42) 92 (90–93)
Cytology 1568 9 (5–14) 88 (86–89) 10 (7–15) 87 (85–88)
Abbreviations: CI, 95% confidence interval; NPV, negative predictive value; PPV,
positive predictive value; Sens, sensitivity; Spec, specificity.
doi:10.1371/journal.pone.0040305.t002
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1100) both equal to 72%, which indicates the improvement over
use of NMP22 alone where sensitivity (123/183) and specificity
(742/1100) both equal 67% (72% versus 67%, difference = 4.3%
[95% CI=1.5–7.0%], McNemar’s test P = 0.002). In combination
with NMP22 at 10 U/mL the MCM5 test removes false negatives
from the NMP22 test, offering an improvement from the 54%
sensitivity of NMP22 alone to 75% sensitivity with 65% specificity
(2800-cell cut-point), or to 80% sensitivity with 58% specificity
(1900-cell cut-point), or to maximal sensitivity of 85% with 45%
specificity (1000-cell cut-point).
In the combination analysis, with NMP22 (10 U/mL cut-point)
and Mcm5 (4200-cell cut-point, where sensitivity and specificity
are equal), 100% (31/31) of muscle invasive cancers (i.e. stage $
T2), 93% (40/43) of pT1 tumours and 53% (54/102) of pTa
tumours were detected. The total number of patients with
carcinoma in situ was low and 86% (6/7) were detected. Grade
1 disease was identified in 46% (10/22), grade 2 disease in 64%
(68/106) and grade 3 disease in 96% (53/55) of cases (including 6/
7 cases of carcinoma in situ). Importantly, Mcm5 combined with
NMP22 identified 95% (79/83, 95% CI= 88–99%) of potentially
life threatening diagnoses (i.e. grade 3 or CIS or stage $pT1) with
high specificity (72%, 95% CI=69–74%).
Discussion
In an earlier proof-of-concept study we showed that elevated
Mcm5 levels in urine cell sediments are highly predictive of
bladder cancer [19]. The prospective blinded observational trial
reported here, involving a large patient cohort, confirms our initial
observations that Mcm5 is a sensitive and specific biomarker for
detection of UCC. Importantly, through multi-ROC analysis, we
show here that the Mcm5 test, in combination with NMP22 at the
established cut-point 10 U/mL, enhances diagnostic accuracy
over NMP22 in isolation and identifies nearly all potentially life
threatening disease.
Despite numerous studies over the last decade, the reported
accuracy of the NMP22 test is highly variable. Many of the earlier
studies recruited small to moderate numbers of subjects and
reported high sensitivities and specificities, above 80% [23–26].
However, a wide range in test performance has been observed in
more recent studies with sensitivity ranging from 33% to 100%
and specificity from 40% to 93% [4]. A pooled analysis including
more recent trials suggests a sensitivity of around 68% and a
specificity of 79% [4]. A recent large multi-institutional interna-
tional trial revealed a marked variability in the performance of the
NMP22 test across participating institutions with sensitivity and
specificity ranging from 36% to 86% and 50% to 94% respectively
[27]. Variability has been attributed to many confounding factors
including biological, analytical and epidemiological variables and
methodological bias.
Our study represents the largest prospective observational trial
ever undertaken using the NMP22 urinary biomarker. Notably,
the performance at the 10 U/mL cut-point, with a sensitivity of
53% and specificity of 84%, is somewhat below that reported in
the pooled analysis, but almost identical to the diagnostic
performance reported in the Matritech supported large patient
cohort trials using the NMP22 point-of-care proteomic assay
[4,28]. Interestingly we observed significantly greater diagnostic
accuracy of NMP22 in females compared to males. Gender
differences in NMP22 test performance have been previously
noted [29,30] however our data represent the largest study of this
question and clearly establishes a clinically meaningful difference
in test performance.
Table 3. False positive rates for the Mcm5 and NMP22 tests across benign conditions.
Test Benign condition n Test value, med (IQR) Pa FPR, %b Pc
Mcm5d Clear normal 661 1040 (,1000–2645) 30
BPH 132 ,1000 (,1000–2438) 0.056 27 0.37
Calculi 106 1840 (,1000–3963) ,0.001 44 0.004
Nephrological 40 ,1000 (,1000–2448) 0.25 25 0.47
Prostatitis 14 ,1000 (,1000–3433) 0.37 29 0.88
Urethral stricture 21 1100 (,1000–2620) 0.94 29 0.86
UTI 246 ,1000 (,1000–2823) 0.84 30 0.92
Other 81 1110 (,1000–2855) 0.68 28 0.71
NMP22e Clear normal 589 2.20 (,2.00–5.30) 11
BPH 110 ,2.00 (,2.00–5.60) 0.96 13 0.65
Calculi 96 2.55 (,2.00–9.48) 0.047 23 0.001
Nephrological 38 2.05 (,2.00–6.43) 0.93 11 0.9
Prostatitis 13 ,2.00 (,2.00–3.50) 0.14 0 0.2
Urethral stricture 18 2.85 (,2.00–6.83) 0.36 17 0.47
UTI 222 3.35 (,2.00–8.63) ,0.001 22 ,0.001
Other 68 2.80 (,2.00–8.03) 0.018 24 0.004
For each subgroup, only those patients with a test results were considered.
Abbreviations: BPH, benign prostatic hyperplasia; FPR, false positive rate; IQR, interquartile range; med, median; UTI, urinary tract infection.
aMann-Whitney test, comparison of test value with normal.
bFalse positive rate determined using 2150-cell cut-point for Mcm5 test and 10 U/mL cut-point for NMP22 test.
cChi-squared test, comparison of false positive rate with Normal group.
dExcludes 53 ‘‘other cancers’’ of the 1354 patients without UCC having an Mcm5 test value.
eExcludes 47 ‘‘other cancers’’ of the 1201 patients without UCC having an NMP22 test value.
doi:10.1371/journal.pone.0040305.t003
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The analysis of false positive Mcm5 results in this study also
revealed an unexpected difference between the male and female
groups. The overall false positive rate in females was 38%
compared to 26% in males. Rather than being related to benign
pathology, the difference was most marked in the clear normal
group. These findings require further investigation. Possible causes
could be fungal contamination by vaginal flora (e.g. Candida
species) or mixing of menstrual endometrial contaminants in
samples, both sources of extraneous MCM expressing cells.
Patients with urinary calculi had the highest incidence of false
positive Mcm5 results (44%). As previously reported, higher false
positive rates are expected in patients with urinary calculi due to
the associated mucosal injury, which exposes the underlying
MCM expressing transit amplifying compartment of the transi-
tional epithelium to the urinary tract [8,19,31]. However,
exclusion of patients with calculi from the ROC analysis did not
make a significant improvement to the overall performance,
presumably because they were a relatively small group (data not
shown). Notably, other benign conditions such as urinary tract
infection or benign prostatic hyperplasia were not associated with
false positive Mcm5 results, in keeping with our proof-of-concept
study [19]. In contrast to the Mcm5 test, false positive NMP22
results were linked to urinary tract infection. The different
aetiologies for false positives with Mcm5 and NMP22 may
account for the improved performance observed when combining
the two urinary biomarkers.
Decreasing urinary Mcm5 and NMP22 signals were observed
with lower stage and grade of UCC, and this was associated with
an increasing false negative rate for both tests. Expression of
MCM proteins in bladder cancer is closely linked to grade [15,16]
and thus this trend is expected. The trend is also explained by the
less spontaneous shedding of tumour cells seen in lower grade
lesions due to stronger cell-cell and cell-matrix attachments.
Commercial development of the Mcm5 test is currently underway
and improvements in the assay design to enhance sensitivity are
planned and thus reduced false negative rates in early stage, well-
differentiated tumours are anticipated. The trend for higher grade
and stage tumours to exhibit higher Mcm5 levels could provide a
useful predictive clinical role e.g. to target imaging and rigid
cystoscopic diagnostic procedures for high risk patients identified
by urinary Mcm5. This potential role requires further study.
Current routine initial investigations for haematuria or other
symptoms suggestive of bladder cancer include flexible cystoscopy
and rigid white light cystoscopy. However an estimated 10–40% of
tumours can be missed due to poor visualization as a result of
inflammatory conditions or bleeding and flat urothelial lesions
such as severe dysplasia and carcinoma in situ [32–34].
Photodynamic diagnosis is a technique that can enhance tumour
detection but its increased sensitivity is associated with higher false
positive rates leading to additional unnecessary investigations,
biopsies and thus increased cost [35]. Urinary biomarkers also
have potential to enhance tumour detection and identify tumours
not visualized during initial endoscopy. A systematic review of the
clinical effectiveness and cost-effectiveness of photodynamic
diagnosis, cytology and urine biomarkers, including FISH,
ImmunoCyt and NMP22, for detection and surveillance of
bladder cancer has recently been undertaken [4]. Urinary cytology
had the lowest pooled sensitivity of the markers studied at 44%
although specificity was highest at 96%. The range of reported
sensitivity for cytology was 7–100%. Thus while our study reports
low sensitivity for cytology this is not a unique finding. Pooled
analyses performed by Mowatt et al showed similar diagnostic
performance with NMP22 (sensitivity 84%, specificity 75%) and
FISH (sensitivity 76%, specificity 85%) with ImmunoCyt slightly
outperforming them (sensitivity 84% specificity 75%) [4]. Notably,
of eight diagnosis and follow-up strategies included in a
probabilistic sensitivity analysis using combinations of photody-
namic diagnosis, flexible cystoscopy, white light cystoscopy,
Table 4. Comparison of Mcm5 and NMP22 test performance across grade and stage.
Test n Test value, med (IQR) Pa Pb Pc FNR, % (CI) Pa Pb Pc
Mcm5d Normal 1354 1015 (,1000–2790) 69 (66–71)
Gradee 1 23 1300 (,1000–5310) 0.14 52 (31–73) 0.085
2 123 4070 (1170–12900) ,0.001 0.041 37 (28–46) ,0.001 0.16
3 55 40900 (5800–122000) ,0.001 ,0.001 ,0.001 11 (4–22) ,0.001 ,0.001 ,0.001
Stagee pTa 115 2590 (,1000–5710) ,0.001 46 (37–56) ,0.001
pT1 48 39000 (5818–136250) ,0.001 ,0.001 10 (3–23) ,0.001 ,0.001
$pT2 38 19850 (7150–65800) ,0.001 0.28 ,0.001 13 (4–28) ,0.001 0.69 ,0.001
NMP22f Normal 1201 2.40 (,2.00–6.30) 84 (82–86)
Gradeg 1 25 ,2.00 (,2.00–8.45) 0.31 80 (59–93) 0.55
2 112 10.20 (2.68–39.83) ,0.001 ,0.001 49 (40–59) ,0.001 0.005
3 51 62.50 (9.90–145.50) ,0.001 ,0.001 ,0.001 25 (14–40) ,0.001 0.005 ,0.001
Stageg pTa 109 6.00 (,2.00–24.50) ,0.001 62 (53–71) ,0.001
pT1 45 31.30 (5.70–125.90) ,0.001 ,0.001 29 (16–44) ,0.001 ,0.001
$pT2 34 70.65 (22.68–258.50) ,0.001 0.099 ,0.001 21 (9–38) ,0.001 0.40 ,0.001
Abbreviations: CI, 95% confidence interval; IQR, interquartile range; med, median; FNR, false negative rate.
aMann-Whitney test (for Test value) or Chi-squared test (for FNR), comparison with Normal group.
bMann-Whitney test (for Test value) or Chi-squared test (for FNR), comparison with previous, i.e. Grade 2 vs Grade 1, Grade 3 vs Grade 2.
cJonckheere-Terpstra test for trend (for Test value) or Chi-squared test for linear by linear association, across Grade or Stage, excluding Normal group.
dData analysis using 2150-cell cut-point for Mcm5 test.
eExcludes 8 CIS and 1 adenocarcinoma from 210 UCC cases having an MCM5 test value.
fData analysis using 10 U/mL cut-point for NMP22 test.
gExcludes 7 CIS from the 195 UCC cases having an NMP22 test value.
doi:10.1371/journal.pone.0040305.t004
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cytology and urinary biomarkers, four were associated with
around a 20% chance of being considered cost-effective. Three
of these four strategies involved the use of either a biomarker or
photodynamic diagnosis. Other urinary markers of bladder cancer
such as Survivin [36], various urinary micro RNAs [37,38] and
epigenetic markers [38] have also been shown to have great
potential as diagnostic markers with sensitivity/specificity reported
.90%. As yet these markers have not been evaluated in large-
scale blinded observational studies thus the initial findings from
these carefully controlled trials should be interpreted with caution.
In this study, the performance of Mcm5 is similar to that of
NMP22 and both markers are significantly more accurate than
urinary cytology. It also outperforms the performance of cytology
from studies combined in a recent systematic review [4]. The
performance of Mcm5 falls below the reported accuracy of
ImmunoCyt and some other novel approaches detailed above. It is
worth noting that Mcm5 initially demonstrated an AUC of 0.93 in
our earlier smaller study and it remains to be seen if the
performance of Survivin and other novel markers is reproducible
in large studies. Our current data suggest that an Mcm5 assay
commercially developed for an end-user laboratory in combina-
tion with NMP22 could be used to modify diagnostic and
surveillance care pathways to enhance the diagnostic accuracy in
those at high risk (e.g. newly presenting visible haematuria patient)
and reduce morbidity and cost of testing in low risk patients (e.g.
newly presenting non-visible haematuria patient without a known
risk factor or a patient with prior low grade non-muscle invasive
tumour). Trials to evaluate modified against standard diagnostic
pathways using a commercialised assay are currently in prepara-
tion.
In conclusion, we have demonstrated that immunofluorometric
detection of Mcm5 in urine sediments is a sensitive and specific
diagnostic test for bladder cancer. The test detects bladder cancers
of all stages and grades. Through evaluation of different assay cut-
points there could be a role for predicting high grade and stage
disease. Importantly, urinary Mcm5 in combination with the
urinary NMP22 measured with the FDA-approved Matritech
NMP22H Test Kit, identifies nearly all life threatening disease.
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